Lineage Cell Therapeutics, Inc. (TLV:LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 19, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,367	403	687	699	1,284	849
Market Cap Growth	137.96%	-41.27%	-1.77%	-45.56%	51.35%	84.30%
Enterprise Value	1,246	289	544	471	1,087	732
Last Close Price	5.51	1.86	3.91	3.92	7.74	5.59
PS Ratio	38.18	11.66	21.32	13.53	95.13	144.57
PB Ratio	19.86	1.44	3.08	2.77	4.54	2.78
P/TBV Ratio	-	5.23	30.84	12.45	11.89	6.86
P/FCF Ratio	-	-	-	307.85	-	-
P/OCF Ratio	-	-	-	187.79	-	-
EV/Sales Ratio	36.94	8.36	16.88	9.11	80.50	124.70
EV/FCF Ratio	-18.02	-	-	207.31	-	-
Debt / Equity Ratio	0.13	0.03	0.05	0.05	0.03	0.04
Debt / FCF Ratio	-	-	-	6.03	-	-
Net Debt / Equity Ratio	-1.82	-0.59	-0.52	-0.75	-0.61	-0.40
Net Debt / EBITDA Ratio	1.92	2.17	1.59	2.48	1.15	1.55
Net Debt / FCF Ratio	1.81	1.91	1.11	-83.56	2.32	1.90
Asset Turnover	0.12	0.09	0.08	0.10	0.03	0.02
Quick Ratio	4.33	3.47	2.02	3.07	2.32	5.35
Current Ratio	4.50	3.65	2.14	3.16	2.37	5.66
Return on Equity (ROE)	-157.75%	-26.73%	-32.07%	-32.37%	-46.52%	-20.05%
Return on Assets (ROA)	-13.65%	-12.53%	-11.80%	-9.44%	-21.77%	-14.16%
Return on Capital Employed (ROCE)	-25.30%	-21.60%	-25.50%	-21.50%	-38.60%	-26.40%
Earnings Yield	-16.38%	-16.80%	-11.27%	-13.21%	-10.42%	-7.82%
FCF Yield	-5.05%	-21.36%	-15.33%	0.33%	-5.79%	-7.51%
Buyback Yield / Dilution	-25.54%	-15.94%	-1.69%	-3.22%	-9.64%	-3.10%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.